trending Market Intelligence /marketintelligence/en/news-insights/trending/tcc3WVbJyhw5l5b5tJ2W4Q2 content esgSubNav
In This List

Epizyme closes $172.5M offering to raise funds for cancer treatment

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Epizyme closes $172.5M offering to raise funds for cancer treatment

Epizyme Inc. has closed a public offering of shares, raising $172.5 million to fund global development of the company's cancer treatment tazemetostat.

Cambridge, Mass.-based Epizyme closed two separate underwritten public offerings of 11.5 million common shares and 350,000 non-voting Series A convertible preferred stock, according to a March 12 press release.

Underwriters fully exercised their option to purchase additional shares in the offering. Each share was offered at $11.50, while each Series A stock was $115 apiece.

The company said net proceeds from the offering will be used to fund global development of tazemetostat outside of Japan. The medicine is under development for epithelioid sarcoma, a rare type of soft tissue cancer, and follicular lymphoma, a type of non-Hodgkin lymphoma. Remaining funds will be used to identify other drug candidates and for working capital and general corporate purposes.

Joint book-running managers on the offering were Jefferies, Citigroup and Cowen, while Wedbush PacGrow acted as lead manager and H.C. Wainwright & Co. as co-manager.